RNA Atrium Therapeutics, Inc.

$10.36▲ +0.10% Healthcare Other
After hours $10.20▼ -1.54% Sep 11, 7:30 PM ET
Volume 247.4K Avg Volume (10D) 378.0K
Key Metrics & Fundamentals
Market Cap
$177.21M
P/E Ratio
–
Div Yield
–%
52W Range
10.00 - 16.77
% vs 50 MA
-17.13%
% vs 200 MA
–%
RSI-14
31.2
MACD Histogram
-0.4500
Beta (1Y vs SPY)
1.18
Free Cash Flow
-$3.96M
Gross Rev
$3.00M
Gross Profit
$3.00M
EBITDA
-$22.28M
COGS
–
Operating Exp
$25.62M
Operating Income
-$22.62M
EBIT
-$22.62M
Pretax Income
-$20.19M
Net Income
-$20.19M
EPS (Diluted)
-1.18
Price & Volume History
Loading chart…
Recent News
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
Insider Monkey · Sep 6, 2026 10:44 AM
Atrium Therapeutics to Participate in Upcoming Investor Conferences
PR Newswire · Sep 2, 2026 12:00 PM
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
Insider Monkey · Aug 28, 2026 7:42 PM
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · Aug 20, 2026 10:23 PM
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
PR Newswire · Aug 13, 2026 8:44 PM
Atrium Therapeutics Earns Another $15 Million Milestone Payment From Bristol Myers Squibb
MT Newswires · Aug 13, 2026 12:40 PM
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
PR Newswire · Aug 13, 2026 12:00 PM
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
The Fly · Aug 6, 2026 1:48 PM
Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome
MT Newswires · Jul 14, 2026 11:18 AM
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
PR Newswire · Jul 14, 2026 10:30 AM
Financial Overview - Income Statement Quarterly

See RNA's money flow as a full page

Social Sentiment
Avg +0.33 · 3 posts
Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
r/stocks · Jan 13, 2025
The post highlights a significant drop in Moderna's sales forecast, indicating investor concern and a bearish sentiment towards the stock.
negative -0.60
NewsDDDiscussionDid a deep dive in this company for absolutely no reason.
r/wallstreetbets · Nov 4, 2024
FDA clearance and Phase 0 trial success are strong positive signals for the company.
positive +0.80
Ripe for picking - (FDMT) 4D Molecular Therapeutics?
r/stocks · Oct 20, 2024
The post presents a highly optimistic financial model and potential for growth, reflecting a bullish outlook on the stock.
positive +0.80
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙